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Abstract
Dopamine plays a key role in the cellular and behavioral responses to drugs of abuse, but the implication of
metabotropic regulatory input to dopaminergic neurons on acute drug effects and subsequent drug-related
behavior remains unclear. Here, we used chemogenetics [Designer Receptors Exclusively Activated by Designer
Drugs (DREADDs)] to modulate dopamine signaling and activity before cocaine administration in mice. We show
that chemogenetic inhibition of dopaminergic ventral tegmental area (VTA) neurons differentially affects locomotor
and reward-related behavioral responses to cocaine. Stimulation of Gi-coupled DREADD (hM4Di) expressed in
dopaminergic VTA neurons persistently reduced the locomotor response to repeated cocaine injections. An attenuated
locomotor response was seen even when a dual-viral vector approach was used to restrict hM4Di expression to
dopaminergic VTA neurons projecting to the nucleus accumbens. Surprisingly, despite the attenuated locomotor
response, hM4Di-mediated inhibition of dopaminergic VTA neurons did not prevent cocaine sensitization, and the
inhibitory effect of hM4Di-mediated inhibition was eliminated after withdrawal. In the conditioned place-
preference paradigm, hM4Di-mediated inhibition did not affect cocaine-induced place preference; however, the
extinction period was extended. Also, hM4Di-mediated inhibition had no effect on preference for a sugar-based
reward over water but impaired motivation to work for the same reward in a touchscreen-based motivational
assay. In addition, to support that VTA dopaminergic neurons operate as regulators of reward motivation toward
Significance Statement
The addictive properties of cocaine and other drugs of abuse are tightly coupled to altered dopamine (DA)
neurotransmission mediated by dopaminergic neurons in the ventral tegmental area (VTA). Here, we used
DREADDs to investigate how modulation of these neurons via G protein–coupled receptors (GPCRs) affects
the behavioral effects of cocaine. The data substantiate dopaminergic VTA neurons as a prime regulator of
explorative locomotion and reward motivation, as well as reveal a delicate role of metabotropic Gi-coupled
input with differential effects during acute, repeated, and sensitized responses to cocaine. The results may
provide an important framework for exploring new principles for addiction treatment via modulation of
GPCR signaling within the dopaminergic system.
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both sugar and cocaine, our data suggest that repeated cocaine exposure leads to adaptations in the VTA that
surmount the ability of Gi-signaling to suppress and regulate VTA dopaminergic neuronal activity.
Key words: addiction; chemogenetics; cocaine; dopamine; G protein–coupled receptors; mouse behavior
Introduction
Addictive drugs all share the common property of caus-
ing elevation of extracellular dopamine (DA) in brain re-
gions related to motor and limbic functions (Di Chiara and
Imperato, 1988). Cocaine elicits its main stimulatory effects
by blocking the reuptake of DA via the DA transporter (DAT),
leading to a rapid increase in extracellular DA levels in areas
receiving dopaminergic innervation (Ritz et al., 1987;
Chen et al., 2006; Torres and Amara, 2007; Durieux et al.,
2012). Although cocaine acts with similar affinity on both
the serotonin and noradrenergic transporters, the behav-
ioral effects of cocaine have been assigned primarily to
altered DA transmission (Chen et al., 2006; Torres and
Amara, 2007; Kristensen et al., 2011). Indeed, seminal
work from the 1980s and 1990s, together with more
recent work, have substantiated an unambiguous role of
DA in cocaine’s actions, including not only the immediate
locomotor-enhancing response but also cocaine-induced
behavioral sensitization and reward-enhancing effects
(Roberts and Koob, 1982; Giros and Caron, 1993; Chen
et al., 2006; Tilley et al., 2009). In the striatum, increased
synaptic levels of DA caused by cocaine lead to enhanced
postsynaptic DA receptor signaling as well as stimulation
of presynaptic G protein–coupled DA D2 autoreceptors,
providing a modulatory feedback loop that enables tight
control of release and firing of DA neurons (Beckstead
et al., 2004; Beckstead and Williams, 2007). It is therefore
not surprising that D2 autoreceptors have been shown to
influence locomotion, reward-processing, drug-cue asso-
ciation, and relapse (Baik, 2013; Ford, 2014). Further-
more, VTA DA neurons receive inhibitory metabotropic
inputs via Gi-coupled glutamate, GABA, and endocan-
nabinoid G protein–coupled receptors (GPCRs; Johnson
and Lovinger, 2016). Their activity, together with iono-
tropic inputs, adjusts the firing rate of DA neurons and DA
release and transmission and has been demonstrated to
influence the behavioral response to cocaine (Glangetas
et al., 2015; Johnson and Lovinger, 2016; Edwards et al.,
2017). These results not only support the assumption that
cocaine requires dopaminergic neuronal activity to increase
extracellular DA (given the re-uptake inhibition by cocaine)
but also suggest strong influence of GPCR signaling in
mesolimbic DAergic neurons on the behavioral responses to
drugs like cocaine. Thus, GPCR signaling in DA neurons
may have major impact on acute cocaine-induced re-
sponses, possibly influencing individual responses to co-
caine and vulnerability to drug addiction (Johnson and
Lovinger, 2016).
To better understand how modulation of VTA DA signaling
and activity affects the acute effects of cocaine and cocaine
reward perception and contributes to the transition toward
addiction, we employed a chemogenetic approach and ex-
pressed Designer Receptors Exclusively Activated by De-
signer Drugs (DREADDs; Armbruster et al., 2007; Ferguson
and Neumaier, 2015; Roth, 2016) in DA neurons of the VTA.
Specifically, we took advantage of the Gi-coupled hM4Di,
which has been shown to reduce phasic firing of neurons by
inducing membrane hyperpolarization through reduced cyclic
adenosine monophosphate (cAMP) signaling and activation of
G protein–coupled inwardly rectifying potassium (GIRK) chan-
nels (Armbruster et al., 2007; Stachniak et al., 2014). Thus,
hM4Di was used as a tool to assess how transient reduc-
tion of VTA DA activity via inhibitory GPCR signaling
cascades affects locomotor and reward-related behaviors
in mice, before and after acute and repeated cocaine
exposures. Our data substantiate the delicate role of VTA
dopaminergic neurons on explorative locomotion and re-
ward motivation but not reward perception, as also indi-
cated by irreversible lesion studies (Kelly et al., 1975;
Roberts and Koob, 1982; Berridge et al., 1989; Berridge
and Robinson, 2016). We specifically provide evidence
that repeated exposure to cocaine leads to major neuro-
nal adaptations in the VTA that overcome the ability of
inhibitory metabotropic input to alter VTA DA-driven be-
haviors, including cocaine-induced locomotion and re-
ward. Furthermore, we find that while inhibition of VTA
dopaminergic neurons has no influence on the expression
of cocaine-induced conditioned place preference, it does
affect subsequent drug-seeking behavior. Likewise, inhi-
bition of VTA dopaminergic neurons had no effect on the
consumption of, and preference for, a sugar reward, but
significantly impaired the motivation to work for that re-
ward in a touchscreen-based assay. These results dem-
onstrate that VTA dopaminergic neurons operate as




TH-Cre mice (Savitt et al., 2005) were bred in-house.
Male mice were used for behavioral experiments, while
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both male and female mice were used for immunohisto-
chemistry and electrophysiological recordings. All exper-
iments were performed in accordance with institutional
guidelines and regulations.
Drugs
Cocaine hydrochloride was dissolved in saline (0.9%).
CNO (Tocris) was dissolved in DMSO (Sigma-Aldrich) and
diluted in saline for a final concentration of DMSO of
0.4%. Both cocaine and CNO were diluted for a final
intraperitoneal (i.p.) administration of 10 ml/kg body-
weight. Equivalent volumes of saline and CNO vehicle
(VEH: 0.4% DMSO) were injected in control animals.
Stereotaxic injections and AAV constructs
Adult wild-type (WT) and hemizygous TH-Cre mice
(8–16 wk old) were bilaterally injected into the VTA (from
bregma: AP –3.3 mm, ML  0.5 mm, from skull DV: 4.5
mm) with adeno-associated virus (AAV) vectors encoding
a Cre-dependent DREADD or control transgene: AAV8-
hSyn-DIO-mCherry, AAV8-hSyn-DIO-hM4Di-mCherry, or
AAV8-hSyn-DIO-rM3Ds-mCherry (Roth, 2016; Vector
Core at University of North Carolina). For projection-specific
targeting, a dual-viral approach was applied; a Cre-
dependent Flp transgene, delivered by retrograde canine
adenovirus 2 (CAV2; CAV2-CMV-DIO-Flp; Schwarz et al.,
2015; Biocampus), was injected into the ventral striatum
(NAc; AP: 1.00, ML: 1.25, DV: –4.5), whereas a Flp-
dependent DREADD transgene, delivered by AAV (AAV8-
hSyn-fDIO-hM4Di-mCherry), was injected into the VTA. This
AAV was manufactured in-house according to the protocol
described previously (Sørensen et al., 2016).
Viral injections were conducted under general isoflurane
anesthesia in a stereotaxic instrument (Kopf Instruments).
Saline droplets were applied to the eyes to prevent drying. A
midline incision was made down the scalp, and a craniotomy
was made using a dental drill for bilateral infusions. On
each side, a volume of 300 nl AAV (titers 1012) was
manually injected over 5 min using a glass cannula cou-
pled to a 10-l Hamilton syringe, which was withdrawn 3
min after the end of the infusion. Before stereotaxic sur-
gery and for 2 d after, mice were subcutaneously admin-
istered an analgesic and antibiotic mixture of Rimadyl and
Baytril (0.5 mg/ml Rimadyl and 1 mg/ml Baytril in saline) at
10 ml/kg body weight. The incision was closed with ab-
sorbable suture, and the mice were given a subcutaneous
saline injection to remain hydrated postsurgery, before
being placed in a cage with heating pads to recover. For
the behavioral studies, each cohort of mice contained an
additional two to three DREADD-injected mice to account
for any exclusions. At the end, 4 of 145 surgerized DREADD
mice were excluded after evaluating viral expression after
end experiments. Behavioral experiments were initiated
after recovery 3 wk postinjections.
Expression verification and histology
Three weeks postinjection, mice injected with AAvs
carrying mCherry, hM4Di-mCherry, or rM3Ds-mCherry
were anesthetized with pentobarbital and transcardially
perfused with cold 4% paraformaldehyde (PFA) in 0.1 M
PBS. Expression of mCherry was assessed by immuno-
histochemistry in coronal sections (40 m) from the stria-
tum and midbrain. Sections were incubated for 20 min in
0.01 M PBS with 0.3% Triton X-100, 5% swine serum, and
1% bovine serum albumin (BSA) to block nonspecific
binding sites, then incubated at 4°C for 24 h in mouse
monoclonal mCherry (1:1000; ClonTech) in 0.01 M PBS
with 0.3% Triton X-100 and 1% BSA. On the second day,
sections were washed in PBS with 0.1% Triton X-100 and
incubated for 60 min with a biotinylated goat anti-mouse
antibody (1:400; Dako) in PBS with 1% BSA, washed
again, and transferred to an avidin–biotin complex for 1 h
(1:250; Vector Laboratories) in PBS-Triton X-100. Finally,
sections were washed and developed using diaminoben-
zidine (DAB), rinsed, mounted on pregelatinized glass
slides, dried, and coverslipped in DePex (BDH Chemi-
cals). Overview images were obtained by use of a light
microscope.
Dual-labeling immunofluorescence was performed as
described elsewhere (Apuschkin et al., 2015) using rabbit
polyclonal TH (1:1000; ADH Diagnostic) and mouse
monoclonal mCherry (1:500; ClonTech) with subsequent
species-appropriate Alexa Fluor 488–conjugated and Al-
exa Fluor 568–conjugated goat secondary antibodies (1:
500; Life Technologies). Sections were mounted and
coverslipped using Prolong Gold antifade reagent (Life
Technologies) and analyzed with a Carl Zeiss AxioScan
microscope.
All mice used for behavioral studies were subjected to
postexperimental validation of midbrain mCherry expres-
sion. Following brain immersion fixation in 4% PFA for 24
h, coronal sections (40 m) from the midbrain (and stria-
tum in the initial cohorts) were mounted and coverslipped
using Prolong Gold anti-fade reagent to assess mCherry
expression directly by epifluorescence microscopy (Zeiss). If
VTA mCherry expression was not detected in both hemi-
spheres of bilaterally injected DREADD mice, they were
excluded from further analysis.
Electrophysiology
Midbrain slices (300 m) were obtained from mice ex-
pressing hM4Di or mCherry using a vibratome (Leica
VT1200). For coronal sections, slicing was performed in a
chilled solution of sodium substituted artificial cerebrospi-
nal fluid (ACSF) containing (in mM) NMDG 125, KCl 2.5,
NaHCO3 26, MgCl2 3, NaH2PO4 1.25, and glucose 25. For
horizontal sections, slicing was performed in a chilled
sucrose-based ACSF solution containing (in mM) sucrose
75, NaCl 67, NaHCO3 26, glucose 25, KCl 2.5, NaH2PO4
1.25, CaCl2 0.5, and MgCl2 7. Slices were transferred after
slicing to 35°C ACSF containing (in mM) NaCl 125, KCl
2.5, NaHCO3 26, CaCl2 2, MgCl2 1, NaH2PO4 1.25, and
glucose 25. The ACSF was continuously bubbled with
95% O2 and 5% CO2, and left for at least 1 h before
measurement.
Patch-clamp recording
Visual patch-clamp recordings of hM4Di-mCherry- and
control mCherry-positive VTA neurons were performed
with an upright microscope (Olympus BX51WI). The sub-
merged recording chamber was continuously perfused
with oxygenated ACSF. Glass pipettes were pulled on a
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puller (Sutter Instruments P87). Coronal sections were
used for CNO puff application experiments, for which the
pipette contained (in mM) K-gluconate 122, Na2-ATP 5,
MgCl2 2.5, CaCl2 0.0003, Mg-Gluconate 5.6, K-Hepes 5,
H-Hepes 5, EGTA 1, Biocytin 10 (Invitrogen), and Alexa
Fluor 488 hydrazide 1. These recordings were performed
in the presence of CNQX (AMPA receptor blocker), gaba-
zin (GABA-A channel inhibitor), and DL-AP5 (NMDA re-
ceptor blocker) to silence synaptic activity and isolate the
postsynaptic effects of hM4Di-mediated inhibition by lo-
cal puff application of CNO (30 M). Control recordings in
slices from non-DREADD-expressing mCherry mice were
performed in ACSF without inhibitors. Horizontal sections
were used for AMPAR/NMDAR recordings, and the re-
cording pipette contained (in mM) Cs-Gluconate 130,
NaCl 8, MgCl2 2.0, EGTA 2, CsCl 6, Hepes 6, QX-314
bromide 5, Na2-ATP3 2.5, and Na2-GTP3 0.5. The pH was
adjusted to 7.3–7.4. Recordings were performed in whole-
cell configuration. The recording electrodes (resistance
4–6 M) were mounted on 3-axis motorized microma-
nipulators (Luigs and Neumann) and connected to CV-7B
Current-Clamp and Voltage-Clamp Headstages (Molecu-
lar Devices). Recordings were acquired with a Multiclamp
700B amplifier and 1440A Digitizer (Molecular Devices).
For AMPAR/NMDAR ratio recordings, picrotoxin was
added to the ACSF. The cells were initially held at –70 mV,
before being depolarized at 40 mV. Synaptic currents
were evoked by stimuli (0.1 ms) at 0.067 Hz through
bipolar stainless-steel electrodes positioned rostrally to
the VTA. If series resistance (measured by –5-mV test
pulse) varied by 25%, the experiment was terminated.
The AMPAR/NMDAR ratio was computed as the aver-
aged EPSC (14 traces) before and after application of
DL-AP5 for minimum 5 min. AMPAR:NMDAR ratio was
calculated by dividing the peak AMPAR-mediated EPSCs
by the peak NMDAR-mediated EPSCs (calculated as the
difference between the EPSC measured in the absence
and presence of DL-AP5).
Behavioral assays
Behavioral experiments were conducted during the
light cycle. Mice were habituated to the test room at least
1 h before initiation of all experiments. For chemogenetic
interventions, CNO (2 mg/kg) was administered i.p. 30
min before the test or the subsequent cocaine injection to
ensure an adequate time span for the DREADDs to ma-
nipulate VTA DA activity. The DREADD experiments were
conducted on cohorts of surgerized mice (n  16–32),
and data were pooled from 2–3 replicate experiments for
habituation, acute response to cocaine, and behavioral
sensitization to cocaine. These experiments were con-
ducted in the order mentioned on the same mice. From
one cohort, the saline control mice were used for the
long-term CNO effect study. Electrophysiology record-
ings, projection-specific acute cocaine response, cocaine
response following repeated cocaine in home cage, con-
ditioned place preference, and reward/motivation assays
were conducted in individual groups of mice in separate
experiments.
Habituation and acute response to cocaine in an
open field test
Mice were placed in the center of square white open
arenas (40  40  40 cm) and monitored for 90 min
(novelty-induced locomotion and habituation) or 180 min
(acute cocaine-induced locomotion). Open-field locomo-
tion was recorded and analyzed using video-tracking soft-
ware (Noldus), and distance traveled was divided into 5-
or 10-min bins. In the novelty-induced locomotion and
habituation tests, mice were administered CNO or VEH in
their home cage 30 min before the test. On the following
day, in the acute cocaine-induced locomotor test, mice
were placed in the center of the arena and allowed to
habituate for 90 min before CNO was administered. After
another 30 min, the mice were given an injection of co-
caine (20 mg/kg) or saline (0.9%), and locomotion was
tracked for an additional 60 min to assess cocaine-
induced locomotion. In a separate cohort of mice, these
open field tests were conducted after repeated treatment
with cocaine in the home cage. For 6 consecutive days,
hM4Di and control mice were administered cocaine (20
mg/kg) at 10 AM in their home cage. One week after the
last injection, the mice were tested in the open field test as
described above.
Behavioral sensitization to cocaine and chronic CNO
effects in activity chamber tests
One week after the acute experiment, the mice under-
took a behavioral sensitization paradigm. This was con-
ducted in novel activity boxes (30  30  20 cm) fitted
with a beam-break movement-detection system (Med As-
sociates). Mice were injected in their home cage with
CNO or VEH 30 min before injection of cocaine (20 mg/kg)
or saline, after which they were placed in the activity box,
and locomotor activity was detected for 60 min. This was
repeated for 6 consecutive days. After 14 d of withdrawal,
the mice received a challenge dose of cocaine (20 mg/kg)
without pretreatment. In a second challenge 1 wk later,
mice were pretreated with CNO 30 min before a challenge
dose of cocaine. On this day, the hM4Di saline control
mice were not injected but placed in the activity box and
tracked for 1 h as previously, as a baseline measure for
chronic CNO test. The following 14 d, these mice received
one daily (9 AM) i.p. injection of CNO or VEH (i.e., the
same as during induction). The day after the last injection,
mice again were placed in the activity box and locomotor
activity was measured.
Cocaine conditioned place preference (CPP): setup
and schedule
CPP experiments were performed in Med Associates
square activity boxes fitted with beam-break movement
detectors. An overview of CPP experimental setup and
schedule is displayed in Fig. 7A. A split wall of red Plexi-
glas separated the chamber into two compartments
(27.3  13.5 cm) to generate a forced-choice procedure
with a predictable-preference design. One compartment,
made of white decorated walls, a white smooth floor, and a
transparent plastic lid was lighter than the other (lux: 50).
The other, darker compartment (lux: 20) contained walls
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decorated with horizontal black and gray stripes, gray
Lego-floor with the bottom side up, and a black plastic lid.
During conditioning, compartments were fully separated
by the split wall. However, on test days, the split wall
contained a small hole (4  4 cm) to allow free passage
between the two compartments. Time in each compart-
ment was recorded, and the red split-walls allowed beam-
break movement detection throughout the test session to
track and analyze locomotor activity as well.
Pretest (day 1–3)
Baseline preference was determined from 3 days of
pretesting before conditioning. On each day, the mice
were placed in the light compartment and allowed to
freely move between the light and dark compartment for a
total of 20 min. Time spent in each compartment was
recorded on each day, and all mice demonstrated a
strong preference for the dark compartment. Therefore,
cocaine was always paired with the less preferred, light
compartment. Individual pretest preferences were rela-
tively stable over the three test sessions, and the average
was used to define baseline preference and groups. Dur-
ing conditioning sessions, mice were pretreated with VEH
or CNO 30 min before cocaine (on conditioning sessions
in the least preferred compartment) and before saline (on
conditioning sessions in the preferred compartment).
Control groups received saline in both compartments;
one group pretreated with VEH, another with CNO, and a
third group pretreated with VEH in the preferred and CNO
in the least preferred compartment (see Fig. 7B).
Place-conditioning (day 4–11)
During the 8 d of conditioning, each mouse was in-
jected with either saline or cocaine (10 mg/kg i.p.) imme-
diately before placement in the appropriate compartment.
To test the effect of CNO in hM4Di mice, CNO or VEH was
injected 30 min before the cocaine/saline injection in the
home cage. Activity levels were recorded throughout
the 30-min session in which the mice were restricted to
the appropriate compartment. Conditioning days were
alternated so that mice were placed in a different com-
partment each day, but the compartments paired with
cocaine, and the days on which they were exposed to this
compartment, were counterbalanced.
CPP test (day 12)
On the day after the last conditioning session, postcon-
ditioning preferences were determined. Mice were again
allowed to freely move between the two compartments
in a 20-min test session where activity and time spent in
each compartment was recorded.
Extinction (day 15–22)
Following establishment of CPP, the mice were daily
placed in the CPP apparatus without any injections and
allowed to freely move between the two compartments for
20 min. Loss of preference for the cocaine-paired com-
partment was followed throughout extinction. The last
test was defined as the day when all mice were no differ-
ent from the baseline preconditioning test for two consec-
utive days.
Reinstatement (10 d after last extinction)
Following a withdrawal phase lasting 10 d from the last
extinction test, all mice received a priming dose of co-
caine (5 mg/kg i.p.) before being placed in the light com-
partment and allowed to freely move between the two
compartments for 20 min.
Reward preference test (RPT)
The RPT was conducted as described elsewhere to as-
sess perception of reward (Humby et al., 2005; Runegaard
et al., 2017). Mice expressing hM4Di, food-deprived to
85%–90% of normal body weight, were exposed to water
and sweetened milk (Mathilde strawberry milk, Arla
Foods) for 20 min over the course of 3 consecutive days
in 2 separate weeks. Drug treatment took place on the
third day of each week, when mice were injected with VEH
or CNO 30 min before the test. Drug treatment was coun-
terbalanced, and mice were randomly allocated to a treat-
ment group with 7 d between treatments.
Must touch: 5-choice serial reaction time task,
must-touch stage
Food-restricted mice were trained in modified nine-hole
operant touchscreen-based chambers (40  34  42 cm;
Campden Instruments) to reach high baseline perfor-
mance at a 1.5-s stimulus duration probe in the 5-CSRTT
as described elsewhere (Caballero-Puntiverio et al., 2017;
Fitzpatrick et al., 2017). Then, mice were injected with
hM4Di and allowed to recover for 3 wk before motiva-
tional aspects of reward were assessed in the must-touch
stage. A lit square on the screen had to be touched to
receive a reward (7 l strawberry milk), which was col-
lected at the reward tray and counted as a correct touch
trial. A new trial was initiated once the mouse left the
reward tray. This challenge took place for 20 min over the
course of 3 consecutive days in 2 separate weeks, with
drug treatment taking place on the third day. Number of
touch trials completed and mean correct and reward
collection latencies were recorded during each test ses-
sion.
High-performance liquid chromatography analysis
Striatal lysates for high-performance liquid chromatog-
raphy (HPLC) analysis of DA content were prepared from
hM4Di mice in the chronic CNO experiment. Following the
locomotor activity test, mice were sacrificed, and follow-
ing rapid dissection of the brain, NAc and dorsal striatum
(dStr) were punched out from coronal slices. Tissue sam-
ples were immediately frozen on dry ice and stored at
–80°C until homogenized in 500 l perchloric acid 0.1 N.
Following centrifugation at 14,000  g for 30 min, 200 l
of the supernatant was filtered through a glass 0.22-m
filter (Avantec 13CP020AS). The samples were analyzed
using EC-HPLC methodology. The concentrations of
monoamines and metabolites were determined by HPLC
with electrochemical detection. The column was a Prod-
igy 3 m ODS-3 C18 (DA 2  100 mm, particle size 3 m,
Phenomenex, YMC Europe). The mobile phase (55 mM
sodium acetate, 1 mM octanesulfonic acid, 0.1 mM Na2EDTA,
and 8% acetonitrile, pH 3.2) was degassed with an online
degasser. Samples (10 l) were injected with a flow rate of
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0.15 ml/min. The electrochemical detection was accom-
plished using an amperometric detector (Antec Decade)
with a glassy carbon electrode set at 0.8 V and an Ag/
AgCl reference electrode. The output was recorded and
peak areas calculated by LC solution software (Shi-
madzu).
Immunoblotting
Dorsal striatum (DStr) was dissected from coronal
slices using a brain matrix and a puncher. Striata were
homogenized in lysis buffer (1% Triton X-100, 0.1% SDS,
1 mM EDTA, 50 mM NaCl, 20 mM Tris, pH 7.5) with added
inhibitor cocktail of proteases (cOmplete Protease Inhib-
itor Cocktail, Roche Diagnostics) and phosphatases
(Phosphatase Inhibitor Cocktail 3, Sigma). Tissue prepa-
rations were mechanically disrupted using a motor-driven
pestle (800 rpm) and mixed by turning them upside down
and rotating at 4°C for at least 10 min. Homogenates were
centrifuged at 16,000  g for 10 min at 4°C to remove
debris. Lysates were prepared for immunoblotting follow-
ing protein determination by a standard BCATM Protein
Assay kit (Thermo Scientific Pierce). Equal amounts of
striatal samples were separated by SDS–polyacrylamide
gel electrophoresis (any kDa gels, Bio-Rad) and trans-
ferred to Immobilon-P membranes (Merck Millipore). The
membranes were blocked in PBS containing 0.05%
Tween 20 and 5% dry milk and incubated overnight with
antibodies against DAT (Millipore, MAB369, 1:1000). For
detection of pTH, blocking was performed in PBS con-
taining 0.05% Tween 20 with 5% polyvinylpyrrolidone-40
(Sigma-Aldrich), and incubated overnight with antibody
against pTH (Cell Signaling, 1:1000). Following incubation
with HRP-conjugated anti-rat or anti-rabbit antibodies
(Thermo Scientific Pierce, 1:2000), the blots were visual-
ized by chemiluminescence (GE Healthcare ECL-kit, GE
Health care Life Sciences) using AlphaEase (Alpha Inno-
tech) and quantified. To verify equal protein loading, the
membranes were reprobed with an HRP-conjugated an-
tibody against -actin (Sigma, 1:10,000) to which protein
levels of DAT and pTH were normalized. Band intensities
were quantified using ImageJ software (v.1.48, NIH).
Experimental design and statistical analyses
Prism software was used for statistical analysis of mo-
lecular and behavioral data with less complex designs
(GraphPad Prism 6). Data were analyzed using unpaired
two-tailed t-tests, one-way ANOVA, or repeated-measures
two-way ANOVA, with Bonferroni’s post hoc test wher-
ever appropriate. For behavioral data with more than two
independent variables, statistical comparisons were con-
ducted using InVivoStat (http://invivostat.co.uk), and data
were analyzed using multifactorial ANOVAs as appropriate.
Significant main effects and interactions were followed by
the relevant pairwise comparisons using the planned com-
parison procedure. Data were log-transformed whenever
required to stabilize the variance and help satisfy the para-
metric assumptions of the analysis. Data are presented as
mean  SEM alongside individual data points in bar
graphs wherever appropriate. Significance level was set
at p 	 0.05. Plots were constructed using GraphPad
Prism 6, and figures were created using Illustrator (Adobe
Systems).
Results
Chemogenetic control of VTA DA neurons
Stereotaxic injection of AAvs encoding Cre-dependent
DREADDs hM4Di-mCherry or rM3Ds-mCherry in the mid-
brain of TH-Cre mice (Fig. 1A) induced robust expression
of mCherry in the midbrain. VTA was stably targeted, with
similar expression patterns observed for hM4Di- and rM3Ds-
mCherry, while no mCherry expression was detected in Cre-
negative (WT) littermates subjected to identical stereotaxic
surgery (Fig. 1B,C). The mCherry expression was confined to
TH-positive neurons within VTA and, although the sub-
stantia nigra (SN) was slightly infiltrated in some in-
stances, it distributed mainly along the mesolimbic
pathway, with axonal mCherry expression primarily seen
in ventral striatum (Fig. 1D; only hM4Di is shown). In
TH-Cre mice, when mCherry was not part of a fusion
DREADD transgene, we observed wider expression of
mCherry in striatum, probably reflecting uneven compart-
mentalization between these transgenes, as the somato-
dendritic expression pattern was similar (Fig. 1E,F). We
confirmed functional DREADD expression by whole-cell
recordings of hM4Di-expressing VTA neurons in coronal
slices. In current clamp mode, hM4Di-expressing neurons
demonstrated transient inhibition of evoked action potentials
on CNO application, consistent with activation of an inhibi-
tory Gi-pathway (Fig. 1G upper trace; n 3). Importantly, no
effect of CNO was observed in control mCherry-expressing
neurons (Fig. 1G lower trace; n  6).
Bidirectional control of novelty-induced locomotor
activity by chemogenetic regulation of Gi- and
Gs-coupled signaling in VTA DA neurons
We next assessed whether bidirectional chemogenetic
modulation of VTA activity altered locomotor activity dur-
ing habituation to a novel environment. Hemizygous TH-
Cre and WT littermates were injected with Cre-dependent
stimulatory (the Gs-coupled rM3Ds) or inhibitory (the Gi-
coupled hM4Di) DREADDs in VTA (Fig. 2A), giving rise to
the following groups; hM4Di (TH-Cre expressing hM4Di),
rM3Ds (TH-Cre expressing rM3Ds) and control mice (WT
with no DREADD expression). Locomotor activity was as-
sessed during a 90-min open field session, initiated 30 min
after i.p. administration of CNO (2 mg/kg) or vehicle (VEH) in
the home cage (Fig. 2B). All groups of mice habituated to the
open field as attested by a significant main effect of time in
a mixed-model analysis (Fig 2C; FTIME(17,1173)  47.95,
p 	 0.0001, FTREATMENT(1,69)  0.50, p  0.48,
FGROUP(2,69) 12.18,p	 0.0001,FGROUP TREATMENT(2,69)
7.36, p  0.0013, n: 12 hM4Di VEH, 17 rM3Ds VEH, 6
control VEH, 15 hM4Di CNO, 12 rM3Ds CNO, 13 control
CNO). Importantly, there was no difference between VEH-
treated control mice (WT), hM4Di-expressing mice, and
rM3Ds-expressing mice, and no difference was observed
between VEH- and CNO-treated control mice (Fig. 2C), as
supported by pairwise comparisons between these
groups. However, pairwise comparisons revealed signifi-
cantly increased locomotion for CNO-treated M3Ds-
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Figure 1. Targeting and modulating VTA dopaminergic signaling with DREADDs. A, Injection of Cre-dependent DREADD virus
(AAV-hSyn-DIO-hM4Di-mCherry or AAV-hSyn-DIO-rM3Ds-mCherry) in the midbrain of TH-Cre mice results in expression of the
DREADD transgene in TH-positive VTA neurons and is distributed along their projections to target regions including ventral striatum.
B, C, Cre-mediated control of expression demonstrated by representative images of mCherry fluorescence in midbrain slices from
TH-Cre (upper panels) and WT (lower panels) mice injected with AAV carrying Cre-dependent hM4Di-mCherry (B) or rM3Ds-mCherry
(C). D, Schematics of coronal sections and area indicated by the light gray square of striatum (left) and midbrain (right), for which
immunofluorescence of TH (turquoise) and hM4Di-mCherry (magenta) is shown individually below, together with a merged zoom of
the dashed rectangular areas. Scale bar 50 m (representative sections, n 9). Numbers over schematic sections indicate distance
from bregma. E, F, Representative immunohistochemical images of mCherry in midbrain (upper panels) and striatum (lower panels)
of TH-Cre mice injected with Cre-dependent hM4Di-mCherry (E) or mCherry (F) in the midbrain (as shown in A) demonstrate that
transgene translocation and expression pattern depend on the transgene. G, Inhibition of action potentials in VTA DA neurons is
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expressing mice and significantly decreased locomotion
for CNO-treated hM4Di-expressing mice, respectively, com-
pared to CNO-treated control mice in the 25- to 85-min time
window (Fig 2C; , p 	 0.0001, , p 	 0.001,
, p 	 0.01, , p 	 0.05 relative to control CNO). Accord-
ingly, the total distance traveled during habituation (Fig. 2D)
revealed no difference between VEH-treated control mice,
hM4Di-expressing mice, and rM3Ds-expressing mice but
was significantly and oppositely changed in CNO-treated
M3Ds-expressing mice and CNO-treated hM4Di-expressing
mice compared to CNO-treated control mice (Fig. 2D;
FTREATMENT(1,69)  0.02, p  0.89, FGROUP(2,69)  14.93,
p	 0.0001, FINTERACTION(2,69) 5.37, p 0.0068, two-way
ANOVA followed by pairwise comparisons between groups).
In addition, within-group comparisons of treatment ef-
fects revealed that CNO reduced the total distance trav-
eled in hM4Di-expressing mice (p  0.0103) and tended
to increase activity of rM3Ds-expressing mice (p 
0.0605). In contrast, CNO had no effect on control mice
(WT) as there was no difference between these control
mice treated with CNO and VEH (p 0.68; Fig. 2D). These
observations suggest that Gi- and Gs-coupled signaling
in TH-positive VTA neurons can substantially and bidirec-
tionally regulate novelty-induced exploratory activity and
habituation to the open field.
VTA inhibition by hM4Di attenuates the acute
locomotor response to cocaine
The suppressed novelty-induced locomotor activity on
CNO stimulation of hM4Di in VTA neurons (Fig. 2C) was
conceivably a result of reduced continuous release of DA.
Since cocaine inhibits DA reuptake via DAT and thereby
increases extracellular DA levels (Giros and Caron, 1993;
Kristensen et al., 2011), we hypothesized that hM4Di-
mediated inhibition would also impair the acute hyperlo-
comotor response to cocaine. The acute effect of cocaine
(20 mg/kg) following hM4Di-mediated inhibition was
assessed in the same open field used for the novelty-
induced locomotor assay, with CNO-treated WT mice
serving as controls. Hence, all groups were pretreated
with CNO, assuming that CNO has no influence on loco-
motion in the control mice, as suggested by the initial
habituation experiments (Fig. 2C). Importantly, TH-Cre
and WT mice injected with hM4Di in VTA were allowed to
habituate in the open field for 90 min before i.p. injection
of CNO (2 mg/kg) 30 min before a saline or cocaine
injection (Fig. 3A). Note, that during the habituation phase
(0–90 min), all four groups showed similar locomotor
activity (Fig. 3A, 0–90 min; FTIME(8400) 86.89, p	 0.001,
FGROUP(1,50) 2.46, p 0.123, FTREATMENT(1,50) 2.06, p 
0.157, mixed-model approach, n: 9 saline control, 12
cocaine control, 12 saline hM4Di, 21 cocaine hM4Di).
While WT mice (controls) exhibited an expected hyperlo-
comotor response to cocaine after CNO pretreatment, the
behavioral response to cocaine was markedly diminished
in TH-Cre mice expressing hM4Di (Fig. 3A, 120–180 min;
FTIME(6,300)  11.57, p 	 0.0001, FGROUP(1,50)  7.68, p 
0.0078 and FTREATMENT(1,50)  36.17, p 	 0.0001, mixed-
model approach followed by planned comparisons;
, p 	 0.001, , p 	 0.01, , p 	 0.05 compared to
cocaine control, n: 9 saline control, 12 cocaine control, 12
saline hM4Di, 21 cocaine hM4Di). Analysis of the total
distance traveled after cocaine treatment (120–180 min)
revealed an overall main effect of group (Fig. 3B,
FGROUP(1,50)  9.71, p  0.003) and treatment (Fig. 3B,
FTREATMENT(1,50) 25, p	 0.0001). Planned comparisons
showed that although cocaine induced a hyperlocomotor
response after CNO pretreatment in both controls
(, p	 0.0001 compared to saline control) and hM4Di-
expressing mice (, p  0.0097 compared to saline
hM4Di), the cocaine-induced locomotor response was
significantly impaired in hM4Di mice (, p  0.0005
compared to cocaine controls; Fig. 3B). Interestingly,
there was no difference between TH-Cre mice expressing
hM4Di and WT control mice treated with saline after
90-min habituation and CNO administration (p  0.3276).
Hence, in contrast to novelty-induced explorative loco-
motor activity, basal locomotion was not affected by
hM4Di-mediated inhibition (Fig. 3A,B). The data support
the view that the behavioral response to cocaine relies on
VTA DA neuronal activity and suggest that engagement of
a Gi-coupled pathway in VTA DA neurons via hM4Di
reduces neuronal activity and prevents cocaine-induced
effects. Besides the acute behavioral hyperlocomotor re-
sponse to cocaine, a single injection of cocaine has been
associated with neuronal plasticity of VTA DA neurons
manifested as an increased AMPAR/NMDAR ratio 24 h
after cocaine exposure (Ungless et al., 2001). An impor-
tant question is whether this effect of cocaine is prevented
by hM4Di-mediated inhibition concomitant with inhibition
of the locomotor response. Interestingly, electrophysio-
logical analysis of acute midbrain slices from hM4Di-
expressing mice 24 h after acute cocaine and CNO
injections showed that this was not the case (Fig. 3C,D).
Patch-clamp recordings of mCherry-positive neurons
demonstrated significantly increased AMPAR/NMDAR
ratio following CNO  cocaine compared to saline
control treatment (Fig. 3E,F; t8  2.89, p  0.02, un-
paired t test, n: 6 sal-sal, 4 CNO-cocaine). Thus,
cocaine-induced plasticity occurred despite attenua-
tion of the acute locomotor response following CNO-
mediated stimulation of hM4Di.
continued
accomplished only in slices expressing hM4Di, not mCherry only, following CNO application. Upper panel: Coronal section of
midbrain slice with dashed rectangle and green arrow indicating area of patch-recording which is shown in a 10-magnification
picture of VTA neurons expressing mCherry-tagged hM4Di (magenta), of which one is patched and shown in 40 magnification with
the position of the patch and CNO puff pipette. Lower panel: Upper trace, representative current clamp recording from a
hM4Di-expressing neuron demonstrating transient inhibition of evoked action potentials following focal application of CNO (30 M);
lower trace, CNO (30 M) application had no effect on an mCherry-expressing VTA neuron.
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Figure 2. Bidirectional effects on locomotor habituation by hM4Di and rM3Ds stimulation in VTA. A, AAV carrying hM4Di or rM3Ds
was injected into the VTA of TH-Cre or WT mice. B, Timeline of the behavioral setup applied to assess habituation of novelty-induced
locomotor activity. CNO or vehicle (VEH) was injected i.p. in the home cage 30 min before placement into the center of an open field
where locomotor activity was recorded and tracked for 90 min. C, Time course of the 90-min habituation of novelty-induced
locomotor activity in an open field 30 min after VEH (left) or CNO (right) injections in control (black), hM4Di-(magenta), or rM3Ds-(blue)
expressing mice. To ease visual inspection, VEH- and CNO-treated mice are shown in different graphs. To aid comparison, the control
mice treated with VEH have been added to the graph showing CNO-treated mice as a dashed gray line. While no significant difference
was found between WT, hM4Di, and rM3Ds mice treated with VEH, CNO demonstrates bidirectional control of novelty-induced
exploratory activity during habituation in hM4Di and rM3Ds mice while leaving WT mice unaffected (FTIME(17,1173)  47.95, p 	
0.0001, FGROUP(2,69)  12.18, p 	 0.0001, FTREATMENT(1,69)  0.50, p  0.48, and FGROUP  TREATMENT(2,69)  7.36, p  0.0013,
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Cocaine-induced locomotion is conveyed by
VTA-NAc projecting DA neurons
Another key question is whether the reduction of the
acute cocaine locomotor response on hM4Di-mediated
inhibition can be fully attributed to VTA DA neurons (as
some degree of expression was found in SN) or even
specific VTA projections. To address this, we adapted a
dual-viral strategy based on application of retrogradely
transported CAV2 (Schwarz et al., 2015) carrying a Cre-
dependent Flp (DIO-Flp) transgene to restrict expression
of a Flp-dependent hM4Di to dopaminergic neurons pro-
jecting from the VTA to NAc (Fig. 4A,B). The CAV2-DIO-
Flp was injected into the ventral striatum, whereas the
Flp-dependent AAV-fDIO-hM4Di-mCherry was injected
into the VTA of TH-Cre and WT mice, resulting in hM4Di-
mCherry expression in TH-Cre mice only (Fig. 4C). When
hM4Di expression was specifically confined to TH-
expressing neurons projecting toward the ventral stria-
tum, we observed a similar reduction in cocaine-induced
hyperlocomotion when CNO was pre-administered (Fig.
4D; FTIME(17,153)  11.55, p 	 0.0001, FGROUP(1,9) 
6.754, p  0.0288, and FINTERACTION(17,153)  3.455, p 	
0.0001, two-way repeated-measures ANOVA, Bonferro-
ni’s post hoc test; , p 	 0.0001,  p 	 0.001, and
, p 	 0.05 relative to WT control, n: 6 WT control, 5
hM4DiVTA¡NAc). Note that although the hM4DiVTA¡NAc
mice seemed to move slightly less during habituation, no
significant difference between the groups was found be-
fore cocaine administration. In addition, assessment of
the total distance traveled during habituation (0–90 min)
revealed no significant difference (Fig. 4E left; t9  2.072,
p  0.0681, unpaired t test), while the total distance
traveled following cocaine (120–180 min) was significantly
reduced in hM4DiVTA¡NAc mice (Fig. 4E right; t9  2.439,
p 0.037, unpaired t test). This suggests that reduction of
cocaine-induced locomotor behavior following VTA DA
hM4Di-mediated inhibition was primarily conveyed by do-
paminergic VTA-NAc projections.
Assessment of repeated hM4Di-mediated inhibition
of VTA DA neurons in a behavioral sensitization
paradigm
We next asked whether inhibition of the behavioral
response to acute cocaine following hM4Di-mediated in-
hibition would translate into an inhibition of behavioral
sensitization on repeated cocaine exposure. Such a sen-
sitization paradigm is thought to reflect the neural adap-
tations that contribute to and possibly gate the transition
to addiction (Kalivas et al., 1998; Steketee and Kalivas,
2011). One week after the initial cocaine exposure, the
same control and hM4Di mice were subjected to repeated
cocaine administration as part of a behavioral sensitiza-
tion protocol. In this experiment, mice were pretreated
with either VEH or CNO in their home cage 30 min before
the cocaine injection that was given immediately before
the mice were placed in activity boxes and monitored for
60 min (Fig. 5A). A group of mice served as saline controls
and included hM4Di-injected TH-Cre and WT mice. These
mice were repeatedly administered saline following pre-
treatment with VEH or CNO and confirmed a CNO-
specific reduction of locomotion during habituation to a
novel environment in hM4Di-expressing mice (Fig. 5B,
induction day 1; F(2,12)  4.688, p  0.031, two-way
repeated-measures ANOVA, Bonferroni’s post hoc test;
, p 	 0.01 compared to CNO control, #, p 	 0.05
compared to VEH hM4Di.). Already on the second day,
novelty-induced locomotion seemed reduced and CNO
appeared not to further reduce locomotion during habit-
uation in hM4Di-expressing mice (Fig. 5B, induction day
2; F(2,12)  3.249, p  0.075, two-way repeated-
measures ANOVA, n: 7 CNO control, 4 VEH hM4Di, 4
CNO hM4Di). These observations support that the effects
of CNO on locomotion are specific for hM4Di-expressing
mice and suggest that hM4Di-mediated inhibition of VTA
DA neurons does not influence basal locomotion. There-
fore, these saline controls were pooled after induction day
1, after which there were no differences between groups
(Fig. 5C).
hM4Di-mediated inhibition of VTA DA neurons does
not prevent behavioral sensitization to cocaine
To address specifically whether hM4Di-mediated inhi-
bition of VTA DA neurons influenced cocaine-induced
locomotion on repeated cocaine exposures, hM4Di-
expressing mice were pretreated with CNO, and the
cocaine-induced locomotor activity was compared to that
of hM4Di-expressing mice pretreated with VEH and WT
control mice pretreated with CNO (Fig. 5C). First, when
comparing to the saline mice, the locomotor activity was
clearly increased in the cocaine groups, but we noticed
that none of the groups showed a gradual sensitization
response to cocaine during the induction phase, which
possibly was a consequence of the previous exposure to
cocaine. Nonetheless, with daily repeated administration of
cocaine (induction days 1–6), both control and VEH pre-
continued
mixed-model approach with group and treatment as between-subjects factors and time as repeated measure, followed by pairwise
comparisons using the planned comparison procedure; , p 	 0.0001, , p 	 0.001, , p 	 0.01, , p 	 0.05 relative to CNO
control, n: 12 hM4Di VEH, 17 rM3Ds VEH, 6 control VEH, 15 hM4Di CNO, 12 rM3Ds CNO, 13 control CNO). D, Representative tracks
and graphs of total distance traveled during the habituation. Analysis of the total distance traveled in VEH- and CNO-treated mice
shows significant reduction and increase in novelty-induced exploration following CNO in hM4Di and rM3Ds mice, respectively,
compared to WT controls (FTREATMENT(1,69)  0.02, p  0.89, FGROUP(2,69)  14.93, p 	 0.0001, FTREATMENTxGROUP(2,69)  5.37,
p  0.0068, two-way ANOVA, followed by planned comparisons between-groups; , p 	 0.05, , p 	 0.01 relative to CNO control,
and within-group; #, p	 0.05 and p 0.06 relative to VEH, n: 12 hM4Di VEH, 17 rM3Ds VEH, 6 control VEH, 15 hM4Di CNO, 12 rM3Ds
CNO, 13 control CNO). Data are shown as mean  SEM.
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Figure 3. hM4Di-mediated inhibition inhibits the acute locomotor response to cocaine but does not prevent potentiation of VTA DA
neurons following cocaine. A, Acute cocaine-induced locomotor activity following habituation assessed in an open field in WT and
TH-Cre mice injected with Cre-dependent hM4Di in the VTA. Distance traveled is shown as meters traveled per 10 min (m/10 min) and
reveals significantly diminished cocaine-induced locomotor response following CNO treatment in TH-Cre mice expressing hM4Di
compared to WT mice that did not express hM4Di (control; 120–180 min; FTIME(6,300)  11.57, p 	 0.0001, FGROUP(1,50)  7.68,
p  0.0078 and FTREATMENT(1,50)  36.17, p 	 0.0001, mixed-model approach followed by planned comparisons; , p 	 0.001,
, p 	 0.01, , p 	 0.05 compared to cocaine control, n: 9 saline control, 12 cocaine control, 12 saline hM4Di, 21 cocaine hM4Di).
B, Representative tracks and graphs with total distance traveled after cocaine injection (120 –180 min). Control mice showed clear
cocaine-induced hyperlocomotor activity, which is impeded in hM4Di mice (FGROUP(1,50)  9.71, p  0.003, FTREATMENT(1,50)  25, p 	
0.0001, mixed-model approach followed by planned comparisons; , p 	 0.0001 cocaine control versus saline control, , p 
0.0097 cocaine hM4Di compared to saline hM4Di, , p  0.0005 cocaine hM4Di compared to cocaine controls, n: 9 saline
control, 12 cocaine control, 12 saline hM4Di, 21 cocaine hM4Di). C, Timeline of experimental setup to assess the influence of
hM4Di-mediated inhibition on the effect of cocaine on AMPAR/NMDAR in VTA DA neurons. As in A, mice expressing hM4Di were
placed in an open field and, after 90-min habituation, injected with CNO, 30 min before cocaine (20 mg/kg). Control mice were
given saline injection. 60 min after cocaine injection, mice were placed back in home cage until the following day, when mice
were sacrificed, and horizontal midbrain sections (as illustrated in D) were prepared for electrophysiology. E, Dot plot of
individual AMPAR/NMDAR ratios 1 d after acute cocaine injection in hM4Di mice treated with CNO compared to hM4Di mice
treated with saline. Stimulation of hM4Di did not prevent cocaine-induced potentiation of VTA DA neurons (t8  2.89, p  0.02,
unpaired t test, n: 6 sal-sal, 4 CNO-cocaine). F, Representative traces of AMPA and NMDA currents. Data are mean  SEM.
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treated hM4Di-expressing mice exhibited a clear and alike
cocaine-induced locomotor response, while locomotor activity
was recurrently attenuated by CNO in hM4Di-expressing mice
(Fig. 5C; FTIME(8,304)  38.71, p 	 0.0001, FGROUP(3,38) 
35.84, p 	 0.0001, and FINTERACTION(24,304)  5.546, p 	
0.0001, two-way repeated-measures ANOVA, Bonferroni’s
post hoc test, , p	 0.0001, , p	0.001, , p	0.01,
, p 	0.05 compared to VEH  cocaine, n: 15 saline
controls (pooled 7 controls and 4 hM4Di pretreated with
CNO and 4 hM4Di pretreated with VEH) and the following
cocaine groups: 10 CNO control, 10 CNO hM4Di, 7 VEH
hM4Di). In contrast to the significant impact of hM4Di-
mediated inhibition on the acute cocaine response (Figs.
3A,B and 4D,E ) as well as on 6 consecutive days during
the induction phase (Fig. 5C and locomotor activity during
Induction day 6 shown in Fig. 5D,E, with the total distance
traveled shown and analyzed in Fig. 5E; F(3,38)  36.06,
p 	 0.0001, one-way ANOVA, Bonferroni’s post hoc test;
, p 	 0.0001, , p 	 0.01 relative to saline control,
###, p 	 0.001 relative to cocaine CNO control and
cocaine VEH hM4Di), 14 d after the last cocaine injection,
there was no effect of hM4Di-mediated inhibition on the
Figure 4. Stimulation of hM4Di selectively in VTA to NAc projecting DA neurons recapitulates the inhibitory effect on cocaine
locomotion. A, B, The two viral vectors used in the dual-viral approach to specify expression of hM4Di to DA neurons projecting from
VTA to NAc; the Flp-dependent DREADD virus, AAV-hSyn-fDIO-hM4Di-mCherry (Vector 1) was injected into the midbrain of TH-Cre
mice and the Cre-dependent CAV2-DIO-Flp (Vector 2) was injected in the ventral striatum to specify hM4Di expression to TH-positive
neurons projecting from VTA to the ventral striatum. C, Representative immunofluorescent images of hM4Di-mCherry (magenta) in
coronal midbrain sections of TH-Cre (hM4DiVTA¡NAc) and WT control. D, Time course of open field session in which the acute
response to cocaine (20 mg/kg) was assessed after 90-min habituation and 30 min with CNO (2 mg/kg), revealing a significant
attenuation of the immediate locomotor response to cocaine (FGROUP(1,9) 6.754, p 0.0288, two-way repeated-measures ANOVA,
n: 6 WT control, 5 hM4DiVTA¡NAc. Bonferroni’s post hoc test; , p	 0.0001,  p	 0.001, and , p	 0.05 relative to WT control).
E, Total distance traveled during habituation (0–90 min; left) and after cocaine administration (120–180 min; right) demonstrates that
while no significant difference between groups was revealed during habituation (t9  2.072, p  0.0681, unpaired t test), activation
of hM4Di specifically in the VTA neurons projecting to NAc is sufficient to dampen the cocaine locomotor response compared to WT
controls (t9  2.439, p  0.037, unpaired t test). Data are mean  SEM.
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Figure 5. Repeated cocaine exposure diminishes the inhibitory effect of hM4Di on locomotor activity. A, Timeline of behavioral
sensitization paradigm conducted 1 wk after the acute cocaine experiment in the open field test. Locomotor activity was tracked for
60 min in activity boxes immediately after cocaine/saline administration on each day of induction (days 1–6) challenge- and context
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expression of behavioral sensitization as determined by a
challenge dose of cocaine (20 mg/kg; Challenge I; Fig.
5C,F,G with total distance traveled shown and analyzed in
Fig. 5G; F(3,38)  6.385, p  0.0013, one-way ANOVA,
Bonferroni’s post hoc test; , p 	 0.01, , p 	 0.05
relative to saline control). Instead, the response to cocaine
was similar to that observed in CNO pretreated WT con-
trol mice and in VEH pretreated hM4Di-expressing mice
(Fig. 5F,G).
Attenuation of cocaine-induced locomotion by
hM4Di signaling is suppressed following repeated
cocaine exposures
In a second challenge 1 wk later (day 28), mice received
an injection of CNO before cocaine. Surprisingly, CNO did
not inhibit the locomotor response to cocaine in either
hM4Di-expressing mice pretreated with CNO or CNO naive
hM4Di-expressing mice that were pretreated with VEH dur-
ing the induction phase (Fig. 5C,H,I, with total distance
traveled shown and analyzed in Fig. 5I; FGROUP(2,24) 
0.7356, p  0.4897, one-way ANOVA, and Fig. 5J;
FTIME(1,24)  4.145, p  0.053, two-way repeated-
measures ANOVA). To further address the lack of effect of
hM4Di after repeated cocaine exposures, another cocaine
experiment was conducted in mice treated repeatedly
with cocaine in their home cages (1 daily injection for 6
consecutive days, with last injection administered 1 week
before the open field test). Again, no difference was ob-
served between these groups of mice (Fig 5K; FTIME(5,40)
13.59, p	 0.0001, FGROUP(1,8) 0.1655, p 0.6948, and
FINTERACTION(5,40)  0.3572, p  0.8746, two-way
repeated-measures ANOVA). Together, these experi-
ments suggest that metabotropic signaling of hM4Di in
VTA DA neurons can suppress both acute and early con-
secutive responses to cocaine, but after more chronic
cocaine exposures, the sensitivity of this signaling is dis-
rupted.
Repeated inhibition of VTA DA neurons by hM4Di
does not affect DA levels and locomotor behavior
Repeated inhibition of VTA DA neurons could poten-
tially cause aberrations in dopaminergic homeostasis
and possibly affect our results. Therefore, DA homeosta-
sis was assessed in hM4Di-expressing mice on the day
after the last injection of 14 d with daily i.p. administration
of CNO (2 mg/kg) or VEH (Fig. 6A). Furthermore, locomo-
tor activity was assessed the day before and after the last
injection of CNO or VEH and revealed no change in
habituation to the activity boxes after chronic CNO
treatment and hM4Di-mediated inhibition (Fig. 6B;
FTIME(5,30)  8.266, p 	 0.0001, FGROUP(1,6)  0.1646,
p  0.699, and FINTERACTION(5,30)  0.3483, p 0.8793,
continued
test days. During induction control (WT) or hM4Di (TH-Cre) mice were treated for six consecutive days with cocaine or saline 30 min
after CNO or VEH pretreatment defining the following groups; saline controls, CNO  cocaine control (WT), CNO  cocaine hM4Di
and VEH cocaine hM4Di. Saline control mice were WT mice pretreated with CNO, hM4Di mice pretreated with CNO, or hM4Di mice
pretreated with VEH. On the Challenge I and context test days, there were no pretreatments, and mice were placed in the activity
boxes immediately after cocaine or saline injections. On the Challenge II test day, all mice were pretreated with CNO 30 min before
the cocaine challenge. B, Locomotor activity of saline-treated mice on the first days of induction, day 1 (left) and 2 (right), shown as
meters traveled per 10 min (m/10 min). Only in the initial phase of habituation on induction day 1, CNO-treated hM4Di mice
demonstrated reduced locomotion during habituation (induction day 1; F(2,12)  4.688, p  0.031, two-way repeated-measures
ANOVA, Bonferroni’s post hoc test; , p 	 0.01 compared to CNO control, #, p 	 0.05 compared to VEH hM4Di. Induction day 2;
F(2,12)  3.249, p  0.075, two-way repeated-measures ANOVA, n: 7 CNO control, 4 VEH hM4Di, 4 CNO hM4Di). From induction
day 2, there was no difference, and saline control groups were pooled for further analysis. C, Total locomotor activity during induction,
challenges, and context control days of cocaine and saline control groups (the latter shown as one group as from induction day 2).
Locomotor activity after cocaine administration was reduced when hM4Di mice were pretreated with CNO during induction
(FGROUP(3,38)  35.84, p 	 0.0001, , p 	 0.0001, , p 	 0.001, , p 	 0.01 , p 	 0.05 compared to VEH  cocaine hM4Di,
Bonferroni’s post hoc tests after significant two-way repeated-measures ANOVA, n: 15 saline controls (pooled 7 controls and 4 hM4Di
pretreated with CNO and 4 hM4Di pretreated with VEH) and the following cocaine groups: 10 CNO control, 10 CNO hM4Di, 7 VEH
hM4Di). D, Locomotor activity on the last day of induction, day 6, shown as m/10 min. E, Representative tracks and graphs of total
distance traveled during the initial 30 min of the test shown in D. On the last day of induction, CNO-treated hM4Di mice moved
significantly less than CNO-treated controls and VEH treated hM4Di mice (F(3,39) 37.22, p	 0.0001, one-way ANOVA. Bonferroni’s
post hoc test;  p 	 0.0001, , p 	 0.01 relative to saline control, ###, p 	 0.001 relative to cocaine CNO control). Likewise,
locomotor activity and representative tracks are shown for challenge I (in F and G), where the mice received a challenge-dose of
cocaine 20 mg/kg immediately before testing and for challenge II (in H and I), where all mice were pretreated with CNO (2 mg/kg) 30
min before the cocaine challenge. G, On Challenge I, all mice treated with cocaine during induction demonstrated significant
increased locomotor activity to the challenge dose compared to mice that during induction were treated with saline (F(3,38)  6.385,
p  0.0013, one-way ANOVA, Bonferroni’s post hoc test; , p 	 0.01, , p 	 0.05 relative to saline control). I, hM4Di stimulation had
no effect on locomotor activity in sensitized mice on a challenge dose of cocaine, as there was no difference in the cocaine-induced
response between groups (FGROUP(2,24)  0.7356, p  0.4897, one-way ANOVA, or in the response between challenge I and
challenge II as shown in J. J, Total distance traveled during the 60 min of each challenge (FTIME(1,24)  4.145, p  0.053, two-way
repeated-measures ANOVA. K, Left: timeline of repeated cocaine administration in home cage and subsequent assessment of CNO
effects on cocaine-induced locomotion in a cocaine challenge. Middle: groups and experimental setup of the cocaine challenge.
Right: cocaine induced locomotor activity of CNO pretreated hM4Di and control mice that have received repeated cocaine injections
in home cage (6 daily injections, the last given a week before the test), shown as m/10 min. The cocaine-induced hyperlocomotor
response in an open field was unaltered by CNO in hM4Di-expressing mice when they have been treated repeatedly with cocaine in
an unrelated environment (home cage), with no difference between hM4Di and control mice treated with cocaine (FGROUP(1,8) 
0.1655, p  0.6948, two-way repeated-measures ANOVA). Data are shown as mean  SEM.
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two-way repeated-measures ANOVA, n  4). In the dis-
sected brains, striatal levels of markers for DA homeosta-
sis, including the phosphorylated (at serine residue 40)
active form of TH (pTH; Lindgren et al., 2000) and DAT,
were similar between CNO- and VEH-administered mice
(Fig. 6C,D; pTH: t6  0.1014, P  0.9225, and DAT: t6 
0.3857, p  0.7130, unpaired t test, n  4). HPLC anal-
ysis did not reveal any changes in total levels of DA in
dStr and NAc, further supporting intact DA homeostasis
following chronic CNO (Fig. 6E; NAc: t6  0.63, p 
0.547, and dStr: t6  0.807, p  0.45, unpaired t test,
n  4). Thus, repeated administration and daily activa-
tion of Gi-signaling in VTA neurons by 2 mg/kg CNO
appears to have negligible influence on overall DA syn-
thesis and turnover and does not alter DA-sensitive
behaviors.
hM4Di-mediated inhibition of VTA during
conditioning does not prevent cocaine-induced
place preference
The acute locomotor data strongly suggest that hM4Di-
mediated inhibition influences VTA neuron activity, DA
release, and subsequent behavior. However, the seem-
ingly intact cocaine sensitization supports that some ef-
fects of cocaine are intact following hM4Di-mediated
inhibition, as also reflected by the increased the AMPAR/
NMDAR ratio (Fig. 3E). We therefore speculated whether
cocaine-induced reward-enhancing effects were altered
on hM4Di-mediated inhibition of VTA neurons. To address
this, we applied a cocaine-induced conditioned place
preference (CPP) paradigm (Fig. 7A,B). Mice expressing
hM4Di in VTA DA neurons were conditioned to cocaine 30
min after pretreatment with CNO or VEH. Strikingly, co-
Figure 6. Chronic CNO administration does not alter basal behavior and DA homeostasis. A, Timeline of the experimental setup to
assess behavioral and cellular effects of repeated CNO administration in TH-Cre mice expressing hM4Di within the DA system.
Locomotor activity was assessed in activity boxes before and after 14 days of daily CNO or VEH injections. Subsequently, brains were
dissected and striatal areas subject to HPLC and WB assays to assess DA homeostatic parameters. B, Locomotion in activity boxes
the day before first injection, and the day after the last injection of 14-days repeated injections of VEH or CNO in mice expressing
hM4Di in VTA DA neurons. Repeated stimulation of hM4Di did not induce adaptations affecting locomotion in the activity box the day
after last injection (FGROUP(1,6) 0.1646, P 0.699 by two-way repeated-measures ANOVA, n 4). C–E, The brains were dissected,
and molecular homeostasis of DA was assayed. There was no change in protein levels of pTH (C) and DAT (D) in dStr as assessed
by WB (pTH: t(6)  0.1014, p  0.9225; DAT: t(6)  0.3857, p  0.7130, unpaired t test, n  4), nor in DA levels of NAc and dStr (E)
as assessed by HPLC (NAc: t(6)  0.63, p  0.547; dStr: t(6)  0.807, p  0.45, unpaired t test, n  4). Data are shown as mean 
SEM. Note, in this experiment, non-DREADD CNO controls were not included.
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Figure 7. hM4Di-stimulation segregates hyperlocomotion from reward in a CPP paradigm. A, Timeline and experimental protocol for
cocaine-induced CPP in mice with hM4Di expression in VTA DA neurons. Below the timeline is an upside-down illustration of the
biased two-compartment apparatus (shown in B) and treatment during the various components of the CPP. During pretest, posttest,
New Research 16 of 26
May/June 2018, 5(3) e0345-17.2018 eNeuro.org
caine induced a preference for the paired compartment in
both CNO-pretreated [cocaine ( CNO)] and VEH-
pretreated mice (Fig. 7C), compared to saline-treated
mice relative to baseline levels (Fig. 7C; F(2,19)  6.549,
p  0.0069, one-way ANOVA, Bonferroni’s post hoc test;
, p 	 0.01, , p 	 0.05 relative to saline, n: 8 saline, 6
cocaine ( CNO), 8 cocaine).
Mice with hM4Di-mediated inhibition of VTA during
conditioning show slower extinction of the
cocaine-induced place preference
Nonetheless, during extinction, we observed a putative
reward-related behavioral difference between mice that
during conditioning were pretreated with CNO and VEH.
That is, the CNO-pretreated hM4Di mice required more
sessions before they extinguished their preference for the
cocaine-paired compartment compared to baseline levels
(Fig. 7D; FTIME(8.152)  8.656, p 	 0.0001, FGROUP(2,19) 
2.174, p  0.1412, and FINTERACTION(16,152)  1.833, p 
0.0315, two-way repeated-measures ANOVA, Bonferro-
ni’s post hoc test; , p 	 0.0001, , p 	 0.001,
, p	 0.01 compared to baseline). Ten days after the last
extinction session, all mice were given a priming dose of
cocaine (5 mg/kg) to assess reinstatement of the previous
cocaine-induced preference. Mice that were not treated
with CNO during conditioning spent significantly more
time in the previously paired compartment compared to
pretest levels (Fig 7D), but there was no significant differ-
ence between the groups on reinstatement (F(2,19) 
1.932, p  0.1723, one-way ANOVA). The distances trav-
eled on hM4Di-mediated inhibition of the VTA neurons by
CNO was also assessed during the last pretest, postcon-
ditioning, and reinstatement. Importantly, VEH pretreated
(cocaine), but not the CNO-pretreated cocaine mice [co-
caine ( CNO)], moved significantly more than saline
control mice in the cocaine-paired compartment during
the drug-free postconditioning and low-dose primed re-
instatement test, respectively (Fig. 7E; FTIME(2,38) 
38.60, p	 0.0001, FGROUP(2,19) 9.012, p 0.0018, and
FINTERACTION(4,38)  5.036, p  0.0023, two-way
repeated-measures ANOVA, Bonferroni’s post hoc test;
, p 	 0.001, , p 	 0.0001 compared to saline-
treated mice). Furthermore, during conditioning sessions,
the VEH-pretreated cocaine mice moved significantly
more than VEH-pretreated saline mice in all sessions, as
well as significantly more than CNO-pretreated cocaine
mice [cocaine ( CNO)] in the third and fourth sessions
(Fig. 7F; FTIME(3,57)  10.22, p 	 0.0001, FGROUP(2,19) 
15.21, p  0.0001, and FINTERACTION(6,57)  7.515, p 	
0.0001, two-way repeated-measures ANOVA, Bonferro-
ni’s post hoc test; , p 	 0.0001, , p 	 0.001,
, p	 0.01 compared to saline-treated mice and ###, p	
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extinction, and reinstatement sessions, partitions with a small opening separated the light and dark compartments, which allowed
mice to freely move between the two compartments during the 20-min sessions. During conditioning, mice were pretreated with CNO
or VEH 30 min before injection of saline or cocaine, after which they were placed in and confined to one of the compartments for 30
min. Cocaine was always given in the least preferred (light) compartment, but treatment and sequence were alternated between
groups. A 3-day pretest period provided a stable baseline for comparison. Eight days of conditioning was followed by a posttest and
active extinction training session until the time spent in the paired compartment was not significantly different from baseline levels.
Ten days after the last extinction day, the mice received a primed cocaine dose of 5 mg/kg to assess reinstatement. B, Illustration
of the CPP apparatus with a light (white walls and smooth floor) and a dark (black and gray striped walls and gray Lego-grip floor)
compartment. Treatment during conditioning (in each compartment) for each of the three groups is shown below. C, Time spent in
cocaine-paired (light) compartment in percentage of baseline (average of pretests for each group) shows significant conditioning of
both cocaine groups when compared to saline-treated mice (F(2,19)  6.549, p  0.0069, one-way ANOVA, n: 8 saline, 6 cocaine (
CNO), 8 cocaine. Bonferroni’s post hoc test; , p 	 0.01, , p 	 0.05 relative to saline). D, Time spent in the cocaine-paired
compartment during baseline, posttest, extinction, and reinstatement demonstrates that while hM4Di-stimulation (i.e. CNO treatment)
before cocaine during conditioning does not prevent cocaine-induced place preference, it prolongs the extinction phase, as these
mice took more sessions before they lost their cocaine-induced place preference (FINTERACTION(16,152)  1.833, p  0.0315, p 	
0.0001, , p 	 0.001, , p 	 0.01 compared to baseline, Bonferroni’s post hoc test after significant two-way repeated-measures
ANOVA). E, Distance traveled in total (shadowed) and cocaine-paired (solid) compartment during the 20-min sessions of baseline,
posttest, and reinstatement. hM4Di-stimulation before cocaine during conditioning prevents context-induced locomotor activity as
well as sensitized response to a lower dose of cocaine, as only VEH pretreated cocaine mice move significantly more than saline
control mice in the cocaine paired compartment during drug-free postconditioning test and low-dose primed reinstatement test
(F(2,19)  9.012, p  0.0018, , p 	 0.0001, , p 	 0.001 compared to saline-treated mice, Bonferroni’s post hoc test after
significant two-way repeated-measures ANOVA). F, Distance traveled of every mouse during the 30 min of each conditioning session
in the cocaine-paired compartment (first through fourth). VEH pretreated cocaine mice move significantly more than VEH pretreated
saline mice in all sessions, show increased locomotor response to cocaine over sessions, and move significantly more than CNO pretreated
cocaine mice in the later sessions (FTIME(3,57)  10.22, p 	 0.0001, FGROUP(2,19)  15.21, p  0.0001, and FINTERACTION(6,57)  7.515,
p 	 0.0001, two-way repeated-measures ANOVA, Bonferroni’s post hoc test;  p 	 0.0001,  p 	 0.001,  p 	 0.01 compared
to saline-treated mice and ###, p	 0.001 compared to CNO pretreated cocaine mice. Within-group comparisons to first session, 
p 	 0.0001,  p 	 0.001). G, Illustration of the CPP apparatus with treatment during conditioning to assess CNO-alone effects on
place preference. H, Time spent in the light (paired) compartment in percentage of baseline (average of pretests for each group) of
saline-conditioned hM4Di mice pretreated with CNO either in both compartments or only in the gray (the latter receiving a VEH
injection before saline in the dark compartment). Dashed gray bars represent the saline control group from the experiment shown in
C and D, included here for comparison. CNO alone had no influence on place preference, with no difference between mice
pre-administered CNO in both compartments or just the one (FTIME(4,80)  3.582, p  0.0097, FGROUP(2,20)  0.1793, p  0.8372,
and FINTERACTION(8,80)  0.8799, p  0.5371, two-way repeated-measures ANOVA). Data are shown as mean  SEM. Note, in these
series of experiments, non-DREADD CNO controls were not included.
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0.001 compared to CNO-pretreated cocaine mice; within-
group comparisons to first session;  p 	 0.0001, 
p 	 0.001). These results highlight a mechanistic disso-
ciation in cocaine-induced responses, in which locomotor
activity is highly affected by hM4Di-mediated inhibition
while reward perception seems essentially unaffected.
Despite the lack of effect of CNO on cocaine-induced
place preference, the extended extinction phase could be
a consequence of CNO and hM4Di-mediated inhibition
alone, which potentially could alter basal preference for
the different compartments. Thus, to circumvent the in-
fluence by hM4Di-mediated inhibition on place preference
with repeated testing, a separate cohort of hM4Di mice
were pretreated with CNO before saline injections in all
conditioning sessions or only light-compartment condi-
tioning sessions (the latter receiving VEH before saline in
the dark compartment; Fig. 7G). In these settings, CNO-
and hM4Di-mediated inhibition of VTA DA neurons alone
did not alter place preference. No difference in time spent
(percentage of baseline) during posttest, repeated testing
(i.e., extinction), and after a priming dose of cocaine (i.e.,
reinstatement) between these two groups or the VEH-treated
saline group from the previous experiment was observed [Fig
7H; FTIME(4,80)  3.582, p  0.0097, FGROUP(2,20)  0.1793,
p  0.8372, and FINTERACTION(8,80)  0.8799, p  0.5371,
two-way repeated-measures ANOVA, n: 7 saline ( CNO), 8
saline ( CNO/VEH), and 8 saline ( VEH)].
Chemogenetic inhibition of VTA DA neurons
decreases motivational aspects of reward but does
not affect perception of reward
To further understand the effect of hM4Di signaling in
reward processing, we asked whether CNO (2 mg/kg) would
alter reward-related responses to natural rewards (i.e.,
sugar) in a reward perception assay and a motivation-based
assay (see Fig. 8A,B,F). We found that hM4Di-mediated
inhibition of VTA DA neurons 30 min before a reward pref-
erence test (Fig. 8B) had no effect on total volumes con-
sumed (Fig. 8C,D; unpaired t test; t14  1.27, p  0.22,
n  8) or on reward preference ratio, sweetened milk
versus water (Fig. 8E; unpaired t test; t14  1.08 p  0.30,
n  8). However, the same dose of CNO significantly
impaired the motivation to work for that same salient
reward in a touchscreen-based motivational assay, in
which the mice had to touch an illuminated square to
obtain sweetened milk (Fig. 8F,G; unpaired t test; t14 
2.83, p  0.01, n  8). The latency from picking up the
reward to touch the screen again was significantly in-
creased (i.e., mean correct latency; Fig. 8H; unpaired t
test; t14  2.28, p  0.04, n  8), while the latency from
touching to picking up the reward (i.e. reward collection
latency) was unaltered (Fig. 8I; unpaired t test; t14  1.11,
p  0.29, n  8).
Discussion
The present work substantiates that DREADDs can be a
powerful tool when attempting to elucidate neuronal
signaling mechanisms underlying discrete natural and
drug-induced behaviors in rodents. Indeed, there is
strong evidence that the synthetic DREADD agonist CNO
is inert in mice, thereby allowing specific temporal activa-
tion of the expressed receptors (Armbruster et al., 2007;
Roth, 2016). It should be noted, however, that recent
studies have suggested conversion following in vivo ad-
ministration in rodents of CNO to clozapine, a DA D2
receptor antagonist (MacLaren et al., 2016; Gomez et al.,
2017). Gomez et al. further reported that clozapine, but
not CNO, crosses the blood–brain barrier and that cloza-
pine binds to and activates the DREADD receptors with
high affinity and potency, while CNO only binds to DRE-
ADDs with low affinity (Gomez et al., 2017). Nonetheless,
although this could explain, for example, the surprisingly
long-lasting behavioral effects observed following CNO-
mediated DREADD activation (Wang et al., 2013), the
results should not affect the conclusions drawn in this
present study. Here, CNO-alone controls were included in
most paradigms and did not reveal any CNO effects in
non-DREADD-expressing mice. Moreover, it is important
to stress that the resulting concentrations of clozapine
predictably are too low to affect D2 receptor function at
concentrations of CNO used (Gomez et al., 2017). This is
also supported by the observed intact cocaine CPP in
CNO-treated mice, given that clozapine has been shown
to block cocaine CPP (Kosten and Nestler, 1994). In addi-
tion, inclusion of both VEH-treated DREADD mice and WT
controls, together with a thorough characterization and val-
idation of the TH-Cre mouse (Runegaard et al., 2017), takes
into account possible confounding factors and allows us to
assign changes in behavior following CNO treatment in TH-
Cre mice injected with hM4Di or rM3Ds to DREADD-
mediated Gi or Gs-signaling in DA neurons.
Our data reveal that injection of CNO in mice express-
ing DREADDs in VTA DA neurons leads to prominent
alterations of both natural and cocaine-induced behav-
iors. For natural behaviors, the results specifically dem-
onstrated how Gi- and Gs-coupled signaling was able to
bidirectionally regulate novelty-induced exploratory activ-
ity and how Gi-coupled signaling impaired motivation to
work for a reward in a touchscreen-based motivational
paradigm. On the other hand, hM4Di-mediated inhibition
had no effect on locomotor activity following habituation
or on reward preference. These results not only substan-
tiate the major role of DA and VTA DA neurons on loco-
motion and reward but also suggest a putative differential
role of VTA DA activity on novelty-induced and basal
locomotor regulation as well as on reward perception and
reward-based motivation. It is possible that these behav-
iors engage VTA DA neurons differently, which could
interfere with the sensitivity of these DA neurons to mod-
ulatory inputs such as hM4Di, even when considering the
expected massive and unspecific activation of hM4Di. In
addition, when targeting VTA DA neurons that have more
recently emerged as a complex heterogeneous popula-
tion of neurons capable of coreleasing GABA (Tritsch
et al., 2014) and glutamate (Hnasko et al., 2010), it is
possible that the DREADD interventions might modulate
neurotransmitters other than dopamine.
The effects on cocaine-induced behaviors were highly
interesting. Stimulation of hM4Di in VTA DA neurons sig-
nificantly attenuated cocaine-induced locomotor hyper-
activity in mice expressing hM4Di in TH-positive neurons
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primarily residing in VTA. In some instances, the SN was
slightly infiltrated, but we found no correlation between
altered behavioral response to CNO and mice with
mCherry-injected neurons in the SN. Moreover, when
hM4Di expression was confined exclusively to VTA-NAc
projections by use of a dual-viral approach, cocaine-
induced hyperlocomotion was attenuated. This confirms
that NAc acts as a primary structure for regulating
cocaine-induced locomotor behavior in line with other
recent reports (Boekhoudt et al., 2016) and earlier studies
suggesting that NAc is primary target for cocaine-induced
responses (Carboni et al., 1989; Adinoff, 2004).
It was striking that hM4Di-mediated inhibition of VTA DA
neurons seemed to be specifically related to the locomotor
effects of cocaine, leaving cocaine conditioning, as as-
sessed by CPP, intact. This suggests that cocaine-induced
hyperlocomotion and the reward-enhancing effects are dis-
tinct processes and might occur through different pathways,
or at least that they are regulated by different mechanisms
within VTA DA neurons. Such a view is supported by previ-
ous investigations segregating cocaine-induced hyperloco-
motion and reward (Zweifel et al., 2008; Eisener-Dorman
et al., 2011; Gifuni et al., 2012). Notably, when NMDARs
were deleted specifically in DA neurons, mice had intact
acute response to cocaine but did not sensitize or exhibit
place preference in one-trial or classic CPP (Zweifel et al.,
2008). Similarly, stimulant, hedonic, and motivational effects
of cocaine can be dissociated and may, like natural rewards
and novelty-induced locomotion, engage the dopamine sys-
tem in very different ways, and therefore seem to be regu-
lated differently by various signaling pathways within VTA
DA neurons.
Figure 8. Stimulation of hM4Di in VTA DA neurons attenuates motivational aspects of reward without affecting reward perception. A,
Timeline of behavioral assessment of reward perception in the reward preference test (as shown in B) and reward motivation in an
operant must-touch test (as shown in F) following CNO treatment in mice expressing hM4Di in VTA DA neurons. B, Illustration of the
reward preference test in which hM4Di mice for three consecutive days spent 30 min in a cage with two bowls at the rear end, one
filled with water and the other with sweetened milk. On the third day, the mice were treated with VEH or CNO 30 min before the test
to assess the influence of hM4Di stimulation on the consumption of water and sweetened milk. C, D, Volumes (ml) of water and
sweetened milk consumed during the test were measured. CNO did not affect the total amount of liquid consumed (D; unpaired t test;
t14  1.27, p  0.22, n  8) or preference for the reinforcer over water (E; unpaired t test; t14  1.08, p  0.3, n  8). F, Illustration
of touchscreen-based operational assay to assess motivation to work for the same sweetened milk reward. Touching the illuminated
field on the touch screen was rewarded by a droplet of milk in the tray at the rear end. Once the reward was consumed, an area lit
up again ready for another touch. The test lasted 20 min or until the mouse had completed 100 trials. Mice expressing hM4Di were
tested for three consecutive days with VEH or CNO treatment on the third day. G–I, CNO significantly reduced the number of touch
trials (G; unpaired t test; t14  2.83, p  0.01, n  8) and mean correct latency (H; unpaired t test; t14  2.28, p  0.04, n  8) but
showed no significant reduction on reward collection latency (I; unpaired t test; t14  1.11, p  0.29, n  8). Data are shown as mean 
SEM. Note, in these series of experiments, non-DREADD CNO controls were not included.
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Table 1. Statistical analysis.
Figure
Data
structure Type of test Sample size Statistical data
2C (left  right)
Open field habituation
following VEH or CNO treatment
(hM4Di, rM3Ds and control mice)
Normal
distribution
Mixed model analysis with two
between-subject factors (group and
treatment) and one repeated measure
(time), followed by Pairwise








FTIME(17,1173)  47.95, p 	 0.0001
FGROUP(2,69)  12.18, p 	 0.001
FTREATMENT(1,69)  0.50, p  0.48
FGENOTYPETREATMENT(2,69)  7.36, p  0.0013
Planned Comparisons, relative




25: hM4Di, , p  0.0064, t  2.731 & rM3Ds,
p  0.324, t  0.99
30: hM4Di, , p  0.042, t  2.03 & rM3Ds,
p  0.14, t  1.47
35: hM4Di, , p  0.016, t  2.41 & rM3Ds,
, p  0.021, t  2.31
40: hM4Di, , p  0.0003, t  3.59 & rM3Ds,
p  0.2827, t  1.07
45: hM4Di, , p 	 0.0001, t  3.95 & rM3Ds,
p  0.07, t  1.8
50: hM4Di, , p 	 0.0001, t3.93 & rM3Ds,
p  0.068, t  1.82
55: hM4Di, , p 	 0.0001, t  5.1 & rM3Ds,
p  0.15, t  1.42
60: hM4Di, , p 	 0.0001, t  4.49 & rM3Ds,
, p  0.0171, t  2.38
65: hM4Di, , p 	 0.0001, t  4.55 & rM3Ds,
p  0.13, t  1.49
70: hM4Di, , p  0.0054, t  2.79 & rM3Ds,
, p  0.0073, t  2.68
75: hM4Di, , p  0.007, t  2.70 & rM3Ds,
p  0.51, t  0.66
80: hM4Di, , p  0.0032, t  2.96 & rM3Ds,
p  0.34, t  0.95
85: hM4Di, , p  0.016, t  2.42 & rM3Ds,
p  0.2, t  1.28
2D
Total distance traveled during open
field habituation with VEH or CNO




Two-way ANOVA followed by









FTREATMENT(1,69)  0.02, p  0.89
FGROUP(2,69)  14.93, p 	 0.0001
FINTERACTION(2,69)  5.37, p  0.0068
Planned Comparison,
Within-treatment, relative to control, df  69;
CNO - hM4Di: , p  0.0012, t  3.39
CNO - rM3Ds: , p  0.010, t  2.66
VEH - hM4Di: p  0.908, t  0.12
VEH - rM3Ds: p  0.255, t  1.15
Within-group, df  69;
Control: p  0.680, t  0.41
hM4Di: , p  0.0103, t  2.63
rM3Ds: p  0.0605, t  1.9
3A
Habituation phase prior to treatment
(0–90 min) (hM4Di and control mice).
Normal
distribution
Mixed-model analysis with two
between subject factors (group







FTIME(8,400)  86.89, p 	 0.0001
FGROUP(1,50)  2.46, p  0.123
FTREATMENT(1,50)  2.06, p  0.157
3A
Acute cocaine response after CNO
and habituation (120–180 min)
(hM4Di and control mice).
Normal
distribution
Mixed-model analysis with two
between-subject factors (group
and treatment) and one
repeated measure (time),
followed by Pairwise Comparisons






FTIME(6,300)  11.57, p 	 0.0001
FGROUP(1,50)  7.68, p  0.0078
FTREATMENT(1,50)  36.17, p 	 0.0001
FGROUP  TREATMENT(1,50)  3.52,
p  0.0667
Planned Comparison, relative
to control, df  350?:
Cocaine hM4Di vs cocaine control:
120: p  0.1362, t  1.49
130: , p  0.0432, t  2.03
140: , p  0.001, t  3.33
150: , p  0.0008, t  3.39
160: , p  0.0027, t  3.01
170: , p  0.0304, t  2.17
180: p  0.0635, t  1.86
3B
Total distance traveled after




Two-way ANOVA followed by pairwise






FGROUP(1,50)  9.71, p  0.003
FTREATMENT(1,50)  25, p 	 0.0001
FINTERACTION(1,50)  2.52, p  0.119
Planned Comparison, df  50?
Within-treatment, hM4Di vs control;
Cocaine: , p  0.0005, t  3.70
Saline: p  0.3276, t  0.99
Within-group, saline vs cocaine;
Control: , p 	 0.0001, t  4.25
hM4Di: , p  0.0097, t  2.69
(Continued)
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Unpaired t test 6 saline-saline:
4 CNO-cocaine
p  0.02, t  2.89, df  8
4D
Acute cocaine response after
CNO including habituation








FTIME(17,153)  11.55, p 	 0.0001,
FGROUP(1,9)  6.754, p  0.0288 and
FINTERACTION(17,153)  3.455, p 	 0.0001
Multiple comparison, Group, df  162
130: p  0.0120, t  3.471
140: p 	 0.0001, t  5.643








Unpaired t test 6 control,
5 hM4DiVTA¡NAc








Unpaired t test 6 control,
5 hM4DiVTA¡NAc
p  0.037, t  2.439, df  9
5B
Cocaine sensitization of
hM4Di and control mice,





followed by Bonferroni’s post-hoc
test on induction day 1
7 CNO control saline,
4 CNO hM4Di saline,
4 VEH hM4Di saline
Induction day 1 (left);
FTIME(5,60)  27.52, p 	 0.0001,
FGROUP(2,12)  4.688, p  0.0313
FINTERACTION(10,60)  1.338,
p  0.2316
Multiple comparison, relative to CNO
hM4Di saline, df  72
VEH hM4Di saline
10: p  0.016, t  2.728
20: p  0.0341, t  2.442
CNO control saline
10: p  0.0024, t  3.367
20: p  0.0075, t  2.998
Induction day 2 (right);
FTIME(5,60)  16.46, p 	 0.0001,
FGROUP(2,12)  3.249, p  0.0745,
FINTERACTION(10,60)  1.344, p  0.2288
5C
Total distances traveled during
cocaine sensitization of hM4Di







15 saline controls (7 CNO controls,
4 CNO hM4Di, 4 VEH hM4Di)
10 CNO control cocaine,
10 CNO hM4Di cocaine,
7 VEH hM4Di cocaine
FTIME(8,304)  38.71, p 	 0.0001,
FGROUP(3,38)  35.84, p 	 0.0001 and
FINTERACTION(24,304)  5.546, p 	 0.0001
Multiple comparison, Group, df  342
CNO hM4Di cocaine vs VEH hM4Di cocaine:
Day1: p  0.171, t  2.20
Day2: p  0.0003, t  4.095
Day3: p  0.121, t  2.335
Day4: p  0.0096, t  3.182
Day5: p  0.0439, t  2.698
Day6: p 	 0.0001, t  4.513
Challenge I: p  0.999, t  0.9513
5E
Cocaine sensitization of hM4Di
and control mice, total distance
traveled during the initial
30 min on day 6 of induction
Normal
distribution
One-way ANOVA followed by
Bonferroni’s post- hoc test
15 saline controls,
10 CNO control cocaine,
10 CNO hM4Di cocaine,
7 VEH hM4Di cocaine
F(3,38)  36.06, p 	 0.0001
Multiple comparison, df  38
CNO hM4Di vs CNO control:
p  0.0004, t  4.518
CNO hM4Di vs VEH hM4Di:
p  0.0002, t  4.710
CNO hM4Di vs saline control:
p  0.0041, t  3.697
VEH hM4Di vs saline control:
p 	 0.0001, t  8.368
CNO control vs saline control:
p 	 0.0001, t  8.646
5G
Cocaine sensitization of hM4Di
and control mice, total distance
traveled during the initial
30 min of Challenge I
Normal
distribution
One-way ANOVA followed by
Bonferroni’s post- hoc test
15 saline controls,
10 CNO control cocaine,
10 CNO hM4Di cocaine,
7 VEH hM4Di cocaine
F(3,38)  6.385, p  0.0013
Multiple comparison, df  38
CNO hM4Di vs saline control:
p  0.0132, t  3.209
VEH hM4Di vs saline control:
p  0.0119, t  3.321
CNO control vs saline control:
p  0.0081, t  3.462
5I
Cocaine sensitization of hM4Di
and control mice, total distance
traveled during the initial
30 min of Challenge II
Normal
distribution
One-way ANOVA 10 CNO control cocaine,
10 CNO hM4Di cocaine,
7 VEH hM4Di cocaine
F(2,24)  0.7356, p  0.4897
(Continued)
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structure Type of test Sample size Statistical data
5J
Cocaine sensitization of hM4Di
and control mice, total distance




Two-way repeated-measures ANOVA 10 CNO control cocaine,
10 CNO hM4Di cocaine,
7 VEH hM4Di cocaine
FTIME(1,24)  4.145, p  0.0530,
FGROUP(2,24)  0.5531, p  0.5823,
FINTERACTION(2,24)  0.2762, p  0.7610
5K
Effect of CNO on cocaine







Two-way repeated measures ANOVA 5 hM4Di cocaine;
5 control cocaine
Day after last injection
FTIME(5,40)  13.59, p 	 0.0001,
FGROUP(1,8)  0.1655, p  0.6948,







Two-way repeated measures ANOVA 4 hM4Di CNO,
4 hM4Di VEH
FTIME(5,30)  8.266, p 	 0.0001,
FGROUP(1,6)  0.1646, p  0.699
FINTERACTION(5,30)  0.3483, p  0.8793
6C-D
Protein levels of pTH and




Unpaired t-test 4 hM4Di CNO,
4 hM4Di VEH
C; pTH:
p  0.9225, t  0.1014, df  6;
D; DAT:
p  0.713, t  0.3857, df  6
6E
Striatal dopamine levels




Unpaired t-test 4 hM4Di CNO,
4 hM4Di VEH
NAc:
p  0.547, t  0.63, df  6
dStr:
p  0.45, t  0.807, df  6
7C
Cocaine conditioned place
preference in hM4Di mice,
time in paired (% of baseline)
Normal
distribution





F(2,19)  6.549, p  0.0069
Multiple comparison, relative to saline, df  19
Cocaine VEH: p  0.0060, t  3.401
Cocaine CNO: p  0.0302, t  2.672
7D
Cocaine conditioned place










FTIME(8.152)  8.656, p 	 0.0001,
FGROUP(2,19)  2.174, p  0.1412
FINTERACTION(16,152)  1.833, p  0.0315;
Multiple comparison, relative to baseline, df  152:
Cocaine VEH:
Post-test: p 	 0.0001, t  5.320
Ext1: p  0.0003, t  4.267
Ext2: p  0.0084, t  3.341
Reinstatement: p  0.0350, t  2.893
Cocaine CNO:
Post-test: p  0.0001, t  4.451
Ext1: p 	 0.0001, t  4.981
Ext2: p  0.0001, t  4.421
Ext3: p  0.0002, t  4.322
Ext4: p  0.0033, t  3.608















FTIME(2,38)  38.60, p 	 0.0001,
FGROUP(2,19)  9.012, p  0.0018
FINTERACTION(4,38)  5.036, p  0.0023
Multiple comparison, relative to saline, df  57:
Cocaine VEH:
Baseline: p  0.999, t  0.4795
Post-test: p  0.0009, t  3.714
Reinstatement: p 	 0.0001, t  5.410
Cocaine CNO:
Baseline: p  0.999, t  0.1025
Post-test: p  0.3743, t  1.335













FTIME(3,57)  10.22, p 	 0.0001,
FGROUP(2,19)  15.21, p  0.0001 and
FINTERACTION(6,57)  7.515, p 	 0.0001;
Multiple comparison, relative to cocaine VEH, df  76:
Saline VEH:
1st: p  0.0005, t  3.823
2nd: p  0.0061, t  3.062
3rd: p 	 0.0001, t  6.121
4th: p 	 0.0001, t  6.768
Cocaine CNO:
3rd: p  0.0002, t  1.787
4th: p  0.0002, t  4.124
Multiple comparison, relative to 1st session, df  57:
Cocaine VEH:
3rd: p  0.001, t  4.408
4th: p 	 0.0001, t  5.843
(Continued)
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While concomitant administration of cocaine and CNO
persistently attenuated cocaine-induced locomotion, we
observed that CNO did not attenuate the sensitized loco-
motor response to cocaine in cocaine-sensitized mice.
Importantly, this may reflect cocaine-induced neuronal
adaptations in the VTA during withdrawal that override the
ability of hM4Di-mediated inhibition to sufficiently sup-
press VTA DA signaling and behavior. In support of this,
repeated cocaine exposure and cocaine sensitization
were recently linked to increased subthreshold activity of
VTA neurons (Arencibia-Albite et al., 2017), which could
reflect a generally impaired function of inhibitory modula-
tory input to VTA. This might relate to the reduced GIRK
channel-mediated currents in midbrain dopaminergic
neurons observed following repeated psychostimulant
exposures (Kobayashi et al., 2007; Padgett et al., 2012).
Regardless of whether this effect is caused by impaired
Gi-coupling due to enhanced activity of the regulator of G
protein signaling (RGS) 2 (Calipari et al., 2014) or desen-
sitization of GIRK channels, it may similarly impair the
functional effect by hM4Di-mediated inhibition in VTA DA
neurons. This could explain why the behavioral effect of
hM4Di-mediated inhibition was absent following with-
drawal after repeated cocaine injections. Desensitization
of the hM4Di receptor is another possibility, but not very
likely because we also observed a lack of effect in sensi-
tized, CNO-naive animals. In addition, desensitization is
unlikely given the relatively high expression levels achieved
with AAV-DREADD delivery and consequently large DRE-
ADD receptor reserve (Roth, 2016). Finally, in another cohort
of mice, CNO- and hM4Di-mediated inhibition had no
influence on cocaine-induced locomotion when the mice
had been treated with repeated cocaine in the home cage
before the test. Therefore, the lack of effect of hM4Di-
mediated inhibition following repeated cocaine conceiv-
ably reflects endogenous adaptations in VTA DA
regulation, adaptations that seem to be independent on
associated cues and context. Accordingly, cocaine-
induced potentiation (Ungless et al., 2001) was not pre-
vented by hM4Di-mediated inhibition before cocaine, as
we found that the AMPAR/NMDAR ratio in VTA neurons
increased independently of CNO. This indicates that
some effects of cocaine are intact and that adaptations
occur despite hM4Di-mediated inhibition and do not in-
volve a general alteration in DA homeostasis as a conse-
quence of repeated CNO- and hM4Di-mediated inhibition
in VTA DA neurons. In summary, the experiments show
that repeated cocaine administration leads to a sensitized
locomotor response to cocaine after a withdrawal period,
independent of whether the locomotor-stimulant effect
was attenuated during sensitization.
Chemogenetic stimulation of Gi-signaling in hM4Di-
expressing neurons is obviously artificial. It should also be
considered that precise subcellular specified signaling to
specific somatodendritic or axonal domains is not al-
lowed, rather only proximately if using DREADD-fusion
constructs (Dong et al., 2010). For this reason, hM4Di
stimulation is usually associated with a general neuronal
inhibition, but given the metabotropic nature of DRE-
ADDs, the effect of CNO in hM4Di mice may be highly
dependent on the overall excitation level of the neurons,
besides the simultaneous modulatory and regulatory in-
puts received by the neurons. This is interesting for the
interpretation of the chemogenetic intervention and should be
considered given the complexity of the results—specifically,
the impaired effect of CNO after repeated cocaine. Our
data indicate a cocaine-mediated impairment of the effect
of CNO in hM4Di mice, and that this effect is not context
related. Although representing a potential caveat on the




structure Type of test Sample size Statistical data
7H
Conditioned place preference
in hM4Di mice following
CNO treatment, time in
paired (% of baseline)
Normal
distribution







FTIME(4,80)  3.582, p  0.0097,
FGROUP(2,20)  0.1793, p  0.8372
FINTERACTION(8,80)  0.8799, p  0.5371
8CD
Reward preference test in




Unpaired t-test 8 hM4Di CNO,
8 hM4Di VEH
p  0.22, t  1.27, df  14
8E
Reward preference test in




Unpaired t-test 8 hM4Di CNO,
8 hM4Di VEH







Unpaired t-test 8 hM4Di CNO,
8 hM4Di VEH







Unpaired t-test 8 hM4Di CNO,
8 hM4Di VEH







Unpaired t-test 8 hM4Di CNO,
8 hM4Di VEH
p  0.29, t  1.11, df  14
Statistical analyses were performed in GraphPad Prism 6, except for behavioral data in Figs. 2 and 3, which were analyzed InVivoStat (Invivostat.co.uk).
*Control mice are wild-type mice injected with the Cre-dependent AAV and do not express the DREADD transgenes.
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provides useful and biological relevant information on the
impact cocaine has on VTA DA signaling and regulation.
In short, it seems that repeated cocaine can disrupt the
sensitivity to metabotropic inputs of VTA DA neurons.
Nonetheless, the major impact by hM4Di-mediated inhi-
bition on the acute response to cocaine suggests significant
metabotropic capacity of VTA DA neurons to prevent the
acute effect of cocaine, which is believed to be due to DAT
blockade at the terminal (as well as cell bodies), leading to
significant increase in dopamine. Interestingly, both soma-
todendritic GABAB and dopamine D2 autoreceptors, among
others (e.g., 5-hydroxytryptamine, muscarinic, and endo-
cannabinoid receptors), on VTA neurons signal via Gi-
coupled receptors and compromise a significant
endogenous modulatory input to VTA DA neurons (Ford,
2014; Johnson and Lovinger, 2016). Indeed, Gi-coupled
GABAB receptors expressed on VTA dopaminergic neurons
were shown to mediate a GABAergic input from NAc
medium spiny neurons that regulate cocaine-induced hy-
perlocomotion (Edwards et al., 2017). Acute conditional
genetic deletion of GABAB receptors in VTA neurons in-
creased the acute locomotor response to cocaine (Ed-
wards et al., 2017), and similar findings were obtained on
conditional genetic deletion of D2 autoreceptors (Bello
et al., 2011). These selective receptor deletion studies
support our findings of a substantial inhibitory influence
by Gi-signaling in mesolimbic DA neurons on acute
cocaine-induced behaviors.
As revealed by a series of DA lesion studies, the “liking”
part of reward processing, at least for natural rewards,
seems independent of DA (Berridge et al., 1989). This has
led to the hypothesis that DA adds incentive value, a
motivational drive to obtain a reward (Berridge and Rob-
inson, 2016; Koob and Volkow, 2016). Our data directly
support this hypothesis, showing that during hM4Di-
mediated inhibition in VTA DA neurons, the motivation to
work for a hedonic reward (sweetened milk) in a learned
must-touch assay is suppressed, while the hedonic value
of the reward itself remains intact. It is tempting to elab-
orate this hypothesis further in relation to the cocaine-
induced responses observed in our CPP paradigm. Thus,
the absent effect of hM4Di-mediated inhibition on cocaine
conditioning could reflect intact reward perception of co-
caine, and the extended extinction phase could reflect
altered encoding of the incentive value of cocaine and
associated cues. It is therefore tempting to propose a
mechanism by which hM4Di-mediated inhibition, in VTA
DA neurons, reduces VTA activity and DA release in NAc,
impairing cocaine-induced increase in DA levels. Conse-
quently, this directly affects locomotor activity but also
impairs the encoding of incentive value to cocaine-paired
cues. The latter may explain the prolonged extinction,
given the role of DA signaling as a vital learning system
based on reward prediction errors that guide responses
according to environmental stimuli (Schultz et al., 1993;
Schultz, 2006). On lack of expected reward, negative DA
signals, so-called negative prediction errors, should facil-
itate adjustment of behavior. Thus, if hM4Di-mediated
inhibition impairs the encoding of incentive value during
cocaine conditioning, it is plausible that these mice re-
spond with smaller negative prediction error signals on
lack of reward during extinction and therefore have lower
motivation to change behavior (i.e., they return to the
preferred dark CPP compartment).
In conclusion, by employing a chemogenetic approach,
we substantiate DA as a prime regulator of reward moti-
vation, as well as reveal a complex and delicate key role of
metabotropic Gi-coupled signaling in regulating VTA DA
output with differential effects during acute, repeated, and
sensitized responses to an addictive drug such as co-
caine. In this way, the data may provide an important
framework for exploring novel strategies and principles for
treatment of addiction via modulation of GPCR signaling
cascades within the dopaminergic system.
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